Register Now: Image-Based Risk: The Next Frontier in Breast Cancer Screening
|Articles|December 4, 1996

Sterling expands DR to 14 x 17 format

Film and digital imaging vendor Sterling Diagnostic Imaging willshowcase its latest work in Direct Radiography, a work-in-progresstechnology for direct conversion of x-rays into digital data.Sterling debuted DR at the RSNA meeting last year in the

Film and digital imaging vendor Sterling Diagnostic Imaging willshowcase its latest work in Direct Radiography, a work-in-progresstechnology for direct conversion of x-rays into digital data.Sterling debuted DR at the RSNA meeting last year in the company'sprevious incarnation as Du Pont's Medical Products group (SCAN12/13/95).

Since then, Sterling, of Glasgow, DE, has worked on expandingthe size of the DR detector to 14 x 17 inches, according to DeborahDuBois, senior vice president and business manager of the DR program.Sterling will demonstrate a 14 x 17 version of DR, and is stilltargeting a commercial release date of 1998 for DR products, DuBoissaid.

Other news at Sterling's booth is the company's major investmentin new printing technology. Sterling in October announced a dealwith Polaroid in which Sterling would buy the assets of Polaroid'sHelios dry-process laser imaging technology (SCAN 11/6/96). Sterlingwill take over manufacturing and marketing of Helios printers,although Polaroid will continue to manufacture Helios film. Sterlingplans to begin selling Helios by January.

In addition to Helios, Sterling last month released detailson its work developing a new non-laser dry printer with Tektronix(SCAN 11/20/96). The as-yet unnamed printer is based on ink-jettechnology developed by Tektronix and adapted for the medicalimaging market by Sterling. Shipments of that product, which willoccupy a lower price point than Helios, are expected in the thirdquarter of 1997.

Related to this article

Emerging Research Insights and New Advances in Neuroradiology
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Current Perspectives on Integrating AI into Radiology
In a recent interview with Diagnostic Imaging, Joseph Cavallo, MD, MBA, offered insights on post-deployment monitoring with AI, the potential for improved workflow efficiency and the ongoing challenge of balancing essential clinical skills and AI literacy in the training of radiology residents and fellows.